Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population
- PMID: 19223085
- DOI: 10.1016/j.ijcard.2009.01.043
Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population
Abstract
Background: Low grade inflammation is of pathogenic importance in the development of cardiovascular disease (CVD) and type 2 diabetes. The inflammation marker YKL-40 correlates with insulin resistance and is highly expressed in atherosclerotic plaques. We aimed to investigate whether YKL-40 could predict overall and cardiovascular (CV) mortality in a 50+ years population without known CVD.
Methods: A representative population sample of 639 individuals aged 50-89 years was recruited from general practices. Examination at baseline included echocardiography and blood and urine samples for CV risk factors and markers including lipids, high sensitive C-reactive protein (hsCRP), N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) and urinary albumin/creatinine-ratio (UACR). Median follow-up period was 5.0 (0.17-5.28) years.
Results: In subjects without diabetes and CVD at baseline, increasing YKL-40 levels independently predicted overall and CV mortality rate with hazard ratios of 1.58 (95% confidence interval (CI), 1.12-2.23, p=0.009) and 1.57 (95% CI, 1.00-2.46, p=0.049) after adjustment for age, sex, smoking, total cholesterol, hsCRP, NT-proBNP and UACR. In combined Kaplan-Meier analyses, baseline values of both YKL-40 and UACR above median significantly predicted increased cumulative overall and CV mortality rates in subjects without diabetes or CVD at baseline (30.6% vs. <or=8%, respectively 10.6%<or=3%, p<0.0001).
Conclusions: YKL-40 seems to be an independent predictor of overall and CV mortality in an elderly part of the general population without diabetes and CVD. YKL-40 and UACR are both independent predictors, that seem to predict overall and CV mortality in a synergistic way.
Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure.Immunobiology. 2012 Jun;217(6):652-6. doi: 10.1016/j.imbio.2011.11.003. Epub 2011 Nov 18. Immunobiology. 2012. PMID: 22209156
-
Plasma YKL-40 levels are elevated in patients with chronic heart failure.Scand Cardiovasc J. 2010 Apr;44(2):92-9. doi: 10.3109/14017430903402218. Scand Cardiovasc J. 2010. PMID: 19961288
-
Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.Immunobiology. 2013 Jul;218(7):945-51. doi: 10.1016/j.imbio.2012.10.015. Epub 2012 Nov 7. Immunobiology. 2013. PMID: 23294528 Clinical Trial.
-
YKL-40--an emerging biomarker in cardiovascular disease and diabetes.Cardiovasc Diabetol. 2009 Nov 23;8:61. doi: 10.1186/1475-2840-8-61. Cardiovasc Diabetol. 2009. PMID: 19930630 Free PMC article. Review.
-
The relationship of vitamin D status to risk of cardiovascular disease and mortality.Dan Med J. 2015 Feb;62(2):B5008. Dan Med J. 2015. PMID: 25634511 Review.
Cited by
-
Variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and prediction of fatal and non-fatal ischemic stroke.PLoS One. 2012;7(8):e43498. doi: 10.1371/journal.pone.0043498. Epub 2012 Aug 24. PLoS One. 2012. PMID: 22937056 Free PMC article.
-
YKL-40 promotes the progress of atherosclerosis independent of lipid metabolism in apolipoprotein E-/- mice fed a high-fat diet.Heart Vessels. 2019 Nov;34(11):1874-1881. doi: 10.1007/s00380-019-01434-w. Epub 2019 May 21. Heart Vessels. 2019. PMID: 31114961
-
A score of low-grade inflammation and risk of mortality: prospective findings from the Moli-sani study.Haematologica. 2016 Nov;101(11):1434-1441. doi: 10.3324/haematol.2016.144055. Epub 2016 Oct 14. Haematologica. 2016. PMID: 27742767 Free PMC article.
-
Diagnostic Value of Serum YKL-40 Level for Coronary Artery Disease: A Meta-Analysis.J Clin Lab Anal. 2016 Jan;30(1):23-31. doi: 10.1002/jcla.21804. J Clin Lab Anal. 2016. PMID: 27152377 Free PMC article.
-
Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial.J Am Heart Assoc. 2024 Mar 5;13(5):e032095. doi: 10.1161/JAHA.123.032095. Epub 2024 Feb 28. J Am Heart Assoc. 2024. PMID: 38416140 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials